article thumbnail

Key Developments from AMCP 2023 on Blockbuster Generics, Diabetes Drugs, PBM Legislation, and More

PM360

Jeff Casberg, MS, RPh, Senior Vice President of Clinical Pharmacy at IPD Analytics, a managed care and pharmaceutical consultancy, highlighted a wide range of 2023 key events that will affect managed care professionals by the end of the year. This product is expected to have three generic launches in 2023.

article thumbnail

Nine for 2023, part three: thriving or surviving?

pharmaphorum

In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceutical companies in 2023 are assessed.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

UnitedHealth-Walmart partnership heats up U.S. Medicare provider competition

Clarivate

For 2023 Medicare Advantage open enrollment, the United States’ largest retailer will begin a 10-year partnership with the nation’s largest insurer. The partnership dovetails with Walmart Health’s plans for 15 new Florida clinics across the Jacksonville, Orlando and Tampa markets by the end of 2023. MA national enrollment.

article thumbnail

The Issues That Matter Most in 2023: Medical Metaverse

Eversana Intouch

Success in 2023 will mean addressing each of those five issues meaningfully – understanding them fully and giving them real action, not just lip service. – is changing, and has big implications for the competitive marketplace. Pharma marketers in 2023 need to: Look for blind spots. or technology, too?

Medical 52
article thumbnail

Breaking through the forecasting fog – 3 trends that will impact critical medicine supply in 2023

pharmaphorum

It’s wise advice from the “Sage of Omaha”; indeed, one highly respected financial newspaper began its 2023 predictions by conceding that it had been wrong on five major counts for 2022. Demand has also increased due to changes in prescribing protocols, leading to a higher underlying number of prescriptions for certain antibiotic medicines.

article thumbnail

Two Key Questions About Payer Strategies in 2023

PM360

However, we expect drugs without strong therapeutic alternatives to have an advantage in negotiations, while drugs in highly competitive classes will be negotiating from a weaker position. Expect the nine competitors to explore Kotler’s 4Ps of Marketing to gain share in this lucrative and competitive marketplace.

article thumbnail

Medical Sales Trends to Watch Out For in 2023

MedReps

If you know how to prepare and get ahead of your competition, reaching your goals will be that much easier. Medical Sales Trends to Watch Out For in 2023 If you want to know what the future holds and create some forward-thinking sales goals, then check out these medical sales trends to watch out for in 2023.